Serán Bioscience
Serán Bioscience raises $200M Venture at $900M valuation
Quick Facts
Serán Bioscience: Venture Funding Round
Serán Bioscience has successfully raised $200M in Venture funding, reaching a valuation of $900M.
Company Overview
Provides development and manufacturing services to pharmaceutical and biotech companies
Funding Details
The Venture round was led by Foresite Capital, with participation from OrbiMed.
Company Information
- Headquarters: Bend, OR
- Founded: 2017
- Employees: 300+
- Category: Biotech
Investment
Serán Bioscience plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Foresite Capital: Verified investor in Venture
- OrbiMed: Verified investor in Venture
Key Investors
About the Author
Related Company Reports
Torl Biotherapeutics raises $96M Series C at $500M valuation
Torl Biotherapeutics raises $96M in Series C at $500M valuation. Antibody-based immunotherapies for cancer patients...
Nilo Therapeutics raises $101M Series A at $450M valuation
Nilo Therapeutics raises $101M in Series A at $450M valuation. Developing therapies based on neuro-immunology research...
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...